Mission Creek Capital Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,342
Closed -$272K 232
2025
Q4
$272K Sell
5,342
-41,468
-89% -$2.12M 0.05% 181
2025
Q3
$2.6M Buy
46,810
+41,012
+707% +$2.4M 0.51% 50
2025
Q2
$400K Buy
5,798
+43
+0.7% +$2.92K 0.09% 147
2025
Q1
$400K Buy
5,755
+105
+2% +$8.67K 0.1% 151
2024
Q4
$486K Sell
5,650
-12,712
-69% -$1.37M 0.11% 157
2024
Q3
$2.19M Buy
18,362
+395
+2% +$52.7K 0.51% 57
2024
Q2
$2.56M Buy
17,967
+6,525
+57% +$865K 0.65% 42
2024
Q1
$1.47M Buy
11,442
+3,620
+46% +$431K 0.38% 74
2023
Q4
$809K Sell
7,822
-100
-1% -$9.89K 0.21% 122
2023
Q3
$720K Sell
7,922
-660
-8% -$58.1K 0.24% 123
2023
Q2
$694K Sell
8,582
-1,978
-19% -$162K 0.22% 130
2023
Q1
$840K Sell
10,560
-110
-1% -$7.8K 0.29% 111
2022
Q4
$722K Sell
10,670
-950
-8% -$55.7K 0.26% 115
2022
Q3
$579K Sell
11,620
-200
-2% -$10.7K 0.22% 129
2022
Q2
$659K Hold
11,820
0.22% 127
2022
Q1
$656K Hold
11,820
0.18% 146
2021
Q4
$662K Sell
11,820
-400
-3% -$21.7K 0.13% 155
2021
Q3
$587K Sell
12,220
-480
-4% -$23.2K 0.11% 160
2021
Q2
$532K Sell
12,700
-200
-2% -$7.75K 0.09% 159
2021
Q1
$435K Hold
12,900
0.06% 168
2020
Q4
$451K Hold
12,900
0.14% 153
2020
Q3
$448K Sell
12,900
-144
-1% -$4.8K 0.18% 139
2020
Q2
$427K Sell
13,044
-950
-7% -$30.3K 0.22% 106
2020
Q1
$421K Sell
13,994
-200
-1% -$5.96K 0.23% 98
2019
Q4
$411K Buy
+14,194
New +$393K 0.19% 126

Other funds holding NVO

Mission Creek Capital Partners's NVO Position: Q1 2026 in Review

Mission Creek Capital Partners sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 5,342 shares — an estimated $272K sold.

Mission Creek Capital Partners first reported a position in NVO in Q4 2019 and held it in 25 quarters. The position peaked at $2.6M in Q3 2025. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Mission Creek Capital Partners reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Mission Creek Capital Partners sold 5,342 Novo Nordisk shares in Q1 2026, an estimated $272K.
  • Mission Creek Capital Partners first reported a position in Novo Nordisk in Q4 2019 and held it in 25 quarters.
  • Mission Creek Capital Partners's Novo Nordisk position peaked at $2.6M in Q3 2025.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Mission Creek Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.